Cytek Biosciences, Inc.
CTKB
$3.96
$0.195.04%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.61% | 0.52% | -2.18% | -0.85% | -1.86% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.61% | 0.52% | -2.18% | -0.85% | -1.86% |
| Cost of Revenue | 11.05% | 8.60% | 0.98% | 0.36% | -0.65% |
| Gross Profit | -2.49% | -5.98% | -4.77% | -1.83% | -2.83% |
| SG&A Expenses | 20.71% | 17.51% | 6.63% | 2.95% | -0.17% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.83% | 9.46% | 1.68% | -0.28% | -2.37% |
| Operating Income | -77.16% | -96.78% | -34.50% | -4.04% | 6.26% |
| Income Before Tax | -350.93% | -423.62% | -30.02% | 53.48% | 49.10% |
| Income Tax Expenses | 1,060.21% | 11,368.13% | -52.23% | -189.03% | 179.00% |
| Earnings from Continuing Operations | -557.69% | -1,005.48% | -26.19% | 63.54% | 2.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -557.69% | -1,005.48% | -26.19% | 63.54% | 2.24% |
| EBIT | -77.16% | -96.78% | -34.50% | -4.04% | 6.26% |
| EBITDA | -108.93% | -146.46% | -45.69% | -2.53% | 11.67% |
| EPS Basic | -569.06% | -1,065.02% | -29.32% | 61.64% | -0.82% |
| Normalized Basic EPS | -357.29% | -453.41% | -33.57% | 51.23% | 47.54% |
| EPS Diluted | -534.75% | -911.26% | -29.25% | 60.04% | -0.33% |
| Normalized Diluted EPS | -357.29% | -453.41% | -33.57% | 51.23% | 47.54% |
| Average Basic Shares Outstanding | -1.64% | -2.19% | -2.85% | -3.14% | -3.11% |
| Average Diluted Shares Outstanding | -1.97% | -2.53% | -3.18% | -2.81% | -2.78% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |